Genscript BiotechGNNSF 68 PS Ratio is 3.42 as of Jul. 12, 2026, which is 66% below its 10-year median of 10.00. GuruFocus rates GNNSF with a GF Score™ of 68/100 and a GF Value™ of $2.81 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, Genscript Biotech ranks better than 72.47% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Genscript Biotech's share price is $1.50.
Genscript Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.44. Hence, Genscript Biotech's PS Ratio for today is 3.42.
The historical rank and industry rank for Genscript Biotech's PS Ratio or its related term are showing as below:
GNNSF'
s PS Ratio Range Over the Past 10 Years
Min: 2.23 Med: 10 Max: 44.71
Current: 4.04
During the past 12 years, Genscript Biotech's highest PS Ratio was 44.71. The lowest was 2.23. And the median was 10.00.
GNNSF's PS Ratio is ranked better than 72.47% of 930
companies
in the Biotechnology industry
Industry Median: 9.51
vs GNNSF: 4.04
During the past 12 months, the average Revenue per Share Growth Rate of Genscript Biotech was 60.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 13.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 20.10% per year.
During the past 12 years, Genscript Biotech's highest 3-Year average Revenue per Share Growth Rate was 32.20% per year. The lowest was 4.10% per year. And the median was 24.20% per year.
Back to Basics: PS Ratio
Genscript Biotech (OTCPK:GNNSF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Genscript Biotech PS Ratio Related Terms
Genscript Biotech PS Ratio Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genscript Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Genscript Biotech's Share Price of today is $1.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genscript Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.44.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Genscript Biotech (GNNSF) has a PS Ratio of 3.42 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genscript Biotech and its competitors. This is 66% below median its historical median of 10.00. Over the past decade, Genscript Biotech's PS Ratio has ranged from 2.23 to 44.71. According to the industry distribution chart, Genscript Biotech ranks #256 out of 930 companies in the Biotechnology industry, placing it in the top 27.5%.
Is Genscript Biotech's PS Ratio too high?
Genscript Biotech's current PS Ratio of 3.42 is 66% below median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 44.71. The Biotechnology industry median PS Ratio is 9.51. Genscript Biotech's value of 3.42 is 64% below this industry median. Based on the distribution chart, Genscript Biotech ranks #256 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #256 out of 930 companies for PS Ratio. This puts Genscript Biotech in the upper half of its industry. The industry median PS Ratio is 9.51. Genscript Biotech's value of 3.42 is 64% below this benchmark. Historically, Genscript Biotech's own PS Ratio has ranged from 2.23 to 44.71 over the past decade. While the company's 10-year median is 10.00 vs. the industry median of 9.51, Genscript Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.51, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current PS Ratio of 3.42 is 64% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median PS Ratio is 9.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current PS Ratio is 3.42, which is 66% below median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.81, compared to a current price of $1.50 — trading 46.6% below its estimated fair value. The current PS Ratio is 3.42, which is 66% below median its 10-year median of 10.00 and 64% below the Biotechnology industry median of 9.51. Genscript Biotech's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current PS Ratio is 3.42 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.50 is trading 46.6% below its estimated GF Value™ of $2.81.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
PS Ratio: 3.42 (66% below median its 10-year median of 10.00)
GF Value™: $2.81 vs. price of $1.50 (46.6% below fair value)
Industry Position: 64% below the Biotechnology median (#256 of 930)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
68GF Score
Get the complete analysis for GNNSF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
